Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced breast cancer: HRS-8080 trial targets Hormone-Resistant tumors

NCT ID NCT07024173

First seen Jan 28, 2026 · Last updated May 19, 2026 · Updated 18 times

Summary

This phase 3 trial tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will be randomly assigned to receive either HRS-8080 or another treatment. The main goal is to see if HRS-8080 can delay cancer growth longer than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.